Activity of selected, novel anti-HER2 compounds under development
Compound | Sponsor | Phase | BC patients treated | ORR in study arm | Median PFS in study arm | NCT.gov |
---|---|---|---|---|---|---|
Monoclonal antibodies | ||||||
Margetuximab (+ chemotherapy) [43] | MacroGenics | III | 536 | 25% | 5.8 months | NCT02492711 |
Antibody drug conjugates | ||||||
Trastuzumab deruxtecan [47] | Daiichi Sankyo | II | 184 | 60.9% | 16.4 months | NCT03248492 |
Trastuzumab duocarmazine [49] | Byondis B.V. | I | 48 | 33% | 7.6 months | NCT02277717 |
PF-06804103 [50] | Pfizer | I | 10 | 66% | NA | NCT03284723 |
ARX788 [51] | Ambrx, Inc. | I | 45 | 31% | NA | NCT03255070 |
RC48-ADC [52] | RemeGen | I | 70 | 31% | 5.8 months | NCT03052634 |
A166 [53] | Klus Pharma Inc. | I | 24 | 26% | NA | NCT03602079 |
bsAbs | ||||||
Zanidatamab (ZW25) [54] | Zymeworks Inc. | I | 13 | 46% | NA | NCT02892123 |
PRS-343 [55] | Pieris Pharma, Inc. | I | 16 | 12% | NA | NCT03330561 |
Zenocutuzumab (MCLA-128) (+ trastuzumab & vinorelbine) [56] | Merus N.V. | II | 28 | 19% | NA | NCT03321981 |
TKIs | ||||||
Tucatinib (+ trastuzumab & capecitabine) [57] | Seagen Inc. | II R | 612 | 40% | 7.8 months | NCT02614794 |
Neratinib (+ capecitabine) [42] | Puma Biotech. Inc. | III R | 621 | 33% | 5.6 months | NCT01808573 |
Poziotinib (+ capecitabine) [58] | Spectrum Pharma Inc. | II | 106 | 25% | 4 months | NCT02659514 |
Pyrotinib (+ capecitabine) [59] | Jiangsu HengRui Med. Co. | II | 267 | 67% | 12.5 months | NCT03080805 |
R: randomized; NA: not applicable; PRS: progesterone receptors
PT and SM wrote the first draft of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.
GC received honoraria for speaker, consultancy or advisory rule from Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine and Samsung. The other authors declare no conflict of interest to disclose.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
No funding was provided for this work.
© The Author(s) 2021.